 |
|
Measuring Progress Toward Achieving Hemoglobin A1c Goals in Diabetes Care
Pass/Fail or Partial Credit
Leonard Pogach, MD, MBA;
Michael Engelgau, MD, MS;
David Aron, MD, MS
JAMA. 2007;297:520-523.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Despite increasing recognition of the effect of diabetes on the health of the US population, there has been only modest improvement in glycemic control among most demographic groups from the 1990s to the early 2000s regardless of health care setting.1 Performance measurement should assess quality of care, which is defined by the Institute of Medicine as the degree to which health services for individuals and populations increase the likelihood of desired health outcomes and are consistent with current professional knowledge.2 Consequently, hemoglobin A1c (HbA1c) control is an important intermediate outcome for measuring the quality of care provided to the 21 million Americans with diabetes. However, considerable debate exists concerning which HbA1c levels are appropriate for public reporting when quality assessments are compared across multiple health care systems.
It is important to distinguish between practice guidelines and performance . . . [Full Text of this Article]
Author Affiliations: New Jersey Veterans Healthcare System, East Orange (Dr Pogach); University of Medicine and Dentistry of New Jersey, Newark (Dr Pogach); Centers for Disease Control and Prevention, Atlanta, Ga (Dr Engelgau); and Louis Stokes Cleveland Veterans Affairs Medical Center and Case School of Medicine, Case Western Reserve University, Cleveland, Ohio (Dr Aron).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Oral Hypoglycemics and Diabetic Nephropathy
Hadler
CJASN 2008;3:159-162.
FULL TEXT
Making performance indicators work: experiences of US Veterans Health Administration
Kerr and Fleming
BMJ 2007;335:971-973.
FULL TEXT
"Doctor, How Certain Are We That This Diabetes Medication Is Best for Me?"
Pogach
ANN INTERN MED 2007;147:428-430.
FULL TEXT
Rosiglitazone and Cardiovascular Risk
Bracken et al.
NEJM 2007;357:937-940.
FULL TEXT
|
